Sign inJoin waitlistJoin the waitlist

Peter Enzinger

Director, Center for Esophageal and Gastric Cancer · Mass General Brigham

Credentials: · · ·

History

Center for Esophageal and Gastric Cancer · Mass General Brigham
Present
Mass General Brigham
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
1997–2000
Hospital Saint Louis
1995–1997
Strong West
1992–1995
Brown University
Alpert Medical School
1988–1992
Brown University

Research

Esophageal cancer
Review · New England Journal of Medicine · 2003 · First of 2 authors · 2,407 citations
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
JAMA Oncology · 2018 · 1,507 citations
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 1,452 citations

CF
Charles Fuchs
53 papers
David Ryan
38 papers
Jeffrey Meyerhardt
37 papers
JC
Jeffrey Clark
31 papers
Matthew Kulke
23 papers
Thomas Abrams
20 papers
AZ
Andrew Zhu
19 papers
Brian Wolpin
18 papers · 2 as a fellow
DI
David Ilson
18 papers
Christopher Willett
17 papers
Harvey Mamon
17 papers
LB
Lawrence Blaszkowsky
17 papers

Clinical trials

Pembrolizumab in Refractory Advanced Esophageal Cancer
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2017–2020
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2013–2017
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2011–2024
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2009–2013